leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...6061626364656667686970...235236»
  • ||||||||||  5-fluorouracil / Generic mfg.
    Clinical data, Journal, Metastases:  Clinical outcome and treatment sequences of patients with advanced pancreatic cancer treated with contemporary chemotherapy protocols. (Pubmed Central) -  Feb 1, 2023   
    Combination therapy protocols such as FOLFIRINOX and gemcitabine/nab-paclitaxel (Gem/NP) define standard-of-care...Conclusion In this real world population of PDAC patients treated with contemporary combination chemotherapies, a positive impact of first line FOLFIRINOX was only observed when no second or further line treatment was administered. Intensity-reduced maintenance therapy may lead to superior survival.
  • ||||||||||  Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
    Biomarker, Journal, Circulating tumor DNA, Metastases:  NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. (Pubmed Central) -  Jan 31, 2023   
    However, due to a small study population, the trial was underpowered to detect a significant difference in survival. Conclusions The results of this study confirm that baseline methylated ctDNA is a prognostic marker and indicate that NPY methylation is a promising marker for response monitoring in patients with mCRC.
  • ||||||||||  Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 31, 2023   
    P1/2,  N=60, Completed, 
    Trial primary completion date: Dec 2023 --> Dec 2022 Active, not recruiting --> Completed | N=43 --> 60 | Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date, Metastases:  AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) -  Jan 30, 2023   
    P2,  N=64, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Nov 2022 --> Mar 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal, Metastases:  A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients. (Pubmed Central) -  Jan 29, 2023   
    The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy has been previously demonstrated...Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept.
  • ||||||||||  Chantix (varenicline) / Pfizer
    Frank J. Menolascino Award Lecture: The Search for Better Autism Treatments: Conventional to Complementary/Alternative (Room 302, Moscone South Room Level: Third Level) -  Jan 29, 2023 - Abstract #APA2023APA_221;    
    Varenicline, an A4B3 nicotinic agonist, has 2 case reports claiming significant improvement, but has not had a randomized controlled trial. Other treatments of interest include probiotics, a carbon absorbent of gut bacterial toxins, a GABA modulator, a serotonin receptor inhibitor, essential oils, treatments such as cholesterol or folinic acid supplementation targeting a small subgroup identified by a biological marker (e.g., low cholesterol or MTHFR), and omega-3 fatty acids, broad-spectrum micronutrients, or other nutritional approaches.Learning Objectives Objective One: Distinguish treatments for core symptoms of autism from treatments for associated symptoms Objective Two: Name some evidence-based treatments for autism Objective Three: Describe the rationale for some emerging treatments that require further research Objective Four: Objective Five:
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  A high interferon gamma signature of CD8 T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. (Pubmed Central) -  Jan 24, 2023   
    We performed single-cell RNA sequencing on ten GC specimens pre- and post-neoadjuvant camrelizumab plus mFOLFOX6 to determine the impact of the TME on the efficacy of the combination therapy and the remodeling of TME by the therapy...Our data reveal interactions between the TME and neoadjuvant immunotherapy plus chemotherapy in GC. Importantly, it also highlights the signature of CD8 T cells in predicting response to the combination therapy in GC.